• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

The Impact of Sarilumab on Patient Reported Outcomes


Robert Spiera, M.D., explores sarilumab’s impact on polymyalgia rheumatica, emphasizing reduced steroid use and enhanced quality of life.

This is a video synopsis/summary of a Between the Lines involving Robert Spiera, M.D., and Dana McCormick, R.Ph.

In this insightful discussion between Dana McCormick, R.Ph., and Robert Spiera, M.D., the focus was on analyzing outcomes and their implications for future patient treatments. Spiera emphasized the importance of various outcome features in treating vulnerable populations. Notably, achieving remission by week 12 and reducing steroid use throughout the year, especially in patients who had prior steroid exposure, stood out as a clinically significant outcome. The discussion highlighted the interplay of different outcomes, with patient-reported outcomes favoring treatment with sarilumab.

Spiera elaborated on the positive impact seen in patient-reported outcomes, encompassing improvements in fatigue scores and quality-of-life assessments. The SF-36, measuring both physical and mental components, demonstrated statistically significant benefits from sarilumab treatment. The totality of the data, including reduced steroid usage and improved patient-reported outcomes, contributed to the excitement expressed by Spiera, anticipating FDA approval. The discussion underscores the multifaceted approach to assessing therapies, considering how patients feel, function and survive, with sarilumab demonstrating positive impacts across various domains.

This summary was AI-generated and reviewed by Managed Healthcare Executive® staff.

Related Videos
Video 11 - "Closing Current Gaps within Fertility Benefits and Care"
Video 10 - "Shaping Fertility Coverage: Access, Costs & Medical Needs"
Video 9 - "Denial of Coverage in Fertility Care"
Video 8 - "Risks of Miscarriage and Multiple Births Associated with Fertility Care"
Video 7 - "Fertility Preservation: Egg Freezing Versus Embryo Freezing"
Video 6 - "Family Building Costs, Barriers, and Dropout Rates Associated with Fertility Care"
Video 5 - "Closing Payer Gaps and Improving Fertility Care Access"
Video 4 - "Increasing Employer Coverage and Maximizing Fertility Benefits "
Video 5 - "Relevance of NUTURE Study Findings for Patients, Payers, Providers"
Video 3 - "Improving IVF Success Rates & Utilizing AI in Fertility Health Care"
Related Content
© 2024 MJH Life Sciences

All rights reserved.